Introduction
products can be then reduced readily to their 5-amino analogues 9a,b. Croisy-Delcey et al. achieved the synthesis of Isoquinolin-1-ones are of considerable interest as potential 55 5-methoxy-4-methylisoquinolin-1-one 11 in moderate yield by drugs, particularly the 5-substituted analogues, which are Curtius rearrangement / thermal cyclisation of the acyl azide potent inhibitors of poly(ADP-ribose)polymerases (PARPs).
10.
12 Simple 5-substituted isoquinolin-1-ones and 5-substituted 3,4-one 13 by bromination of 5-bromoisoquinolin-1-one 12 with dihydroisoquinolin-1-ones were reported as long ago as 1991 pyridinium perbromide; this was converted to the lactim 14 to be potent inhibitors of PARPs in vitro and in cells 1,2 and 5-60 and from this they were then able to introduce formyl, methyl hydroxyisoquinolin-1-one 1 (often mis-named as the tautomer and methylthio at the 4-position (forming 15a-c) by lithiation 1,5-dihydroxyisoquinoline 2, Figure 1 ) has shown good inhiband quench with an appropriate electrophile, followed by de 30 ition of the enzyme in vitro and in models of inflammation and other PARP-mediated diseases in vivo. 3 However, of this methylation with hydrogen bromide. 13 There is thus a strong need to develop efficient syntheses of 4,5-disubstituted iso series, it is the 5-amino analogue 5-AIQ 3 which has shown 65 quinolin-1-ones with nitrogen substituents in the 5-position most promise as an inhibitor of PARPs, partly owing to the and opportunities for diversity at the 4-position to be able, exceptional solubility in water of its hydrochloride salt. 5-AIQ inter alia, to explore the structure-activity relationships for 35 3 is active in models in vivo and in vitro of a wide range of inhibition of the numerous isoforms of PARP and other disease states, including colitis, 4 ischaemic heart disease, 5 enzymes. haemorrhagic shock 6 and spinal cord trauma, 7 and has recently been shown to have strong antimetastatic effects in a murine model of cancer. 8 We have recently reported 9 that 5-70 Chemistry 40 benzamidoisoquinolin-1-ones 4 and one 3-substituted 5-benzPalladium-catalysed couplings usually offer great opportun amidoisoquinolin-1-one 5 are selective inhibitors of the ities to introduce a wide range of substituents onto a hetero-PARP-2 isoform; 5-benzoyloxyisoquinolin-1-one 6 also cyclic core under relatively mild conditions, providing chem selectively inhibits PARP-2. 10 ical diversity rapidly and efficiently. Thus these methods were In the light of these biological activities, we wished to ex-75 explored for attachment of the 4-substituents. 5-Nitroisoquin 45 plore 4,5-disubstituted isoquinolin-1-ones. There is a marked olin-1-one 16 (Scheme 2) is readily accessible as a starting paucity of reports of preparation of such compounds in the material carrying the required 5-nitrogen substituent 6, 9 and it chemical journal literature, shown in Scheme 1. We have diswas expected that a halogen could be introduced electrophilicclosed recently that palladium-catalysed cyclisation of Nally to the 4-position, as this is the most nucleophilic in this allyl-2-iodo-3-nitrobenzamide 7a at high-temperature gives 4-80 heterocycle.
14 It proved impossible to iodinate at this position ion or with the subsequent reaction with the electrophile. This lithiation / quench sequence could also not be applied to the introduction of aryl groups at the 4-positions, owing to lack of an appropriate electrophile, so other couplings were sought. 5 Palladium-catalysed couplings are relatively insensitive to the presence of other substituents in the substrates. Stille coupling of 24 with tetramethyltin using a conventional tetra kis(triphenylphosphine)palladium(0) catalyst failed but the Pd 2 (dba) 3 / SPhos catalyst / ligand system introduced by 10 Buchwald 17 for enhancing Suzuki couplings was successful in providing 25 in 72% yield. Similarly, Suzuki coupling of 24 with phenylboronic acid and with 4-trifluoromethylphenyl boronic acid (an electron-poor boronic acid often associated with poor coupling yields 18 ) proceeded very efficiently with 
Scheme 3 shows how the coupled products were converted to the corresponding isoquinolin-1-ones. The lactim unit of 25 was deprotected to the lactam by demethylation with hydro bromic acid to give 4-methyl-5-nitroisoquinolin-1-one 28. 5 From here, simple catalytic hydrogenation of the nitro group provided the 5-amino analogue 29. The 5-aryl-1-methoxyiso quinolines 26a,b were similarly demethylated to the 4-aryl-5 nitroisoquinolin-1-ones 30a,b, which were reduced to the 5 amino-4-arylisoquinolin-1-ones 31a,b.
10
This demethylation is inappropriate to the synthesis of 34 and 31c carrying a 4-(4-methoxyphenyl) group, as this substit uent would also be demethylated by the hydrogen bromide. A modified sequence is shown in Scheme 4, in which the protec ting 1-methoxy group is replaced by a benzyloxy group which 15 can be removed under conditions which retain the 4-(4-meth oxyphenyl) unit. Reaction of the 1-chloro compound 23 with sodium benzyloxide in boiling DMF furnished the required 1 OBn protected compound 33 in moderate yield but a signific ant amount of the 1-dimethylaminoisoquinoline 32 was also 20 isolated. This material arose from thermal degradation of the solvent, liberating highly nucleophilic dimethylamine which reacted with the electrophilic 23. The structure of 33 was con firmed by X-ray crystallography. In this structure (Figure 2 ), the molecule is essentially planar, with the benzyloxy function 25 pointing away from the core. Again, the nitro group is peri to a large group in the 4-position (bromine), resulting in the nitro group being twisted out of plane and the C-Br bond being bent away from the nitro group. Pd-catalysed Suzuki coupling of 33 with 4-methoxyphenylboronic acid smoothly gave a 30 high yield of 34. From here, removal of the benzyl protecting group and reduction of the 5-nitro group was achieved in one step, giving 31c. To provide a severe test of any steric constr aints on this new Suzuki coupling to the 4-bromo-5-nitroiso quinolines, coupling of 33 with phenanthrene-9-boronic acid 35 was attempted. Surprisingly for such a large aromatic group approaching the 4-position of the isoquinoline with the bulky peri 5-nitro group, coupling was effective under the standard conditions, giving a 42% yield of 35. The X-ray crystal struc ture of this highly crowded extended binaphthyl was deter 40 mined ( Figure 2 ). As expected, both the 5-nitro and the 4 phenanthrene substituents are twisted severely out of the plane HBr, 50°C, 65% (30a), 65% (30b); iii, H 2 , Pd/C, EtOH, aq. HCl, 65%; iv, H 2 , Pd/C, EtOH, 51% (31a), 53% (31b).
of the isoquinoline to relieve the steric compression. This is shown by the asymmetry in the angles at C8 involving the phenanthrene (C7-C8-C17 126.6, C9-C8-C17 116.3 o ) and also 45 by the C8-C17-C30-C29 torsion angle of 171 o . Nearest neigh bour 4-phenanthrene groups in the gross structure are approx imately coplanar, with a separation distance of 3.68 Å.The Obenzyl group was removed by hydrogenolysis, with simultan eous reduction of the nitro group, to give 36. This compound 50 was insoluble in all common solvents, precluding both charac terisation by NMR and any biological evaluation.
As 5-benzamidoisoquinolin-1-one 4 was highly selective for inhibition of the PARP-2 isoform, 9 31a was benzoylated at the exocyclic amine to furnish 37 as one example of a 4-sub 55 stituted 5-benzamidoisoquinolin-1-one.
Biochemical evaluation
Selected isoquinoline-1-ones 22, 30a, 31b,c and 37 were eval uated for their inhibition of the catalytic activities of PARP-1 and PARP-2; the data are presented in Table 2 . Comparative 60 data are also given for the non-isoform-selective inhibitor 5 AIQ 3, 9 for 4 (Ar = Ph), which is 9.3-fold selective for inhib ition of PARP-2, 9 and for 6, which is 2.75-fold selective for 5-nitroisoquinolin-1-ones which are generally weaker inhib-PARP-2 9 (60-fold claimed by Pellicciari et al. 10 ). Introduction 10 itors of PARP enzymes. 1 By contrast, 31b, which corresponds of the 4-bromo substituent in 22 led to increase in potency to 5-AIQ 3 but carrying a 4-trifluorophenyl group at the 4 against both PARP isoforms, relative to the lead non-selective position, is four-times less potent than 3 against PARP-1 but 5 inhibitor 5-AIQ 3; notably, the activity against PARP-2 was more inhibitory towards PARP-2. Thus 31b is almost as increased over 4-fold, leading to a 2.6-fold selectivity for inselective (7.6-fold) for PARP-2 as is most selective compound hibition of PARP-2 by 22. The 5-nitro-4-phenyl analogue 30a 15 4 (Ar = Ph; 9.3-fold) reported to date 9 and presents a new lead was non-selective and less potent than was 3, as expected for core to explore further the structural requirements for selec- tivity. Curiously, changing the electron-withdrawing trifluoro methyl group in 31b for an electron-donating methoxy group in 31c decreased binding to PARP-2 and hence selectivity. The most selective lead inhibitor 4 (Ar = Ph) contains a 5 5 benzamido group but including this into the 4-aryl series in 37 completely abolished activity against both isoforms. This is probably owing to the steric crowding between the 4-and 5 peri-substituents evident in the MM2-minimised structure of 37 (Figure 3 ), distorting the bicycle and related to that obser 10 ved in the crystal structure of 35 ( Figure 2 ). Figure 4 shows the results of post facto modelling of the structure of 31b complexed to the NAD + -binding site of human PARP-2. The starting stucture was of human PARP-2 complexed with the non-selective inhibitor ABT888. 19 PARP-2-selective inhibitor 15 31b was then docked into the models using the existing bound inhibitor as template. Once docked, the inhibitor was subjec ted molecular mechanics and dynamics calculations to estab lish optimal docking conformations; during these calculations, the receptor was restrained to its original conformation. 20 Lastly, both the inhibitors and binding pockets (radius 10Å) were subjected to molecular dynamics and finally molecular mechanics calculations to give the final structure ( Figure 3) . 
Conclusions
In this paper, we report that palladium-catalysed couplings (Stille, Suzuki, Buchwald-Hartwig) to the sterically very crowded 4-position of 1-alkoxy-4-bromo-5-nitroisoquinolines 30 24 and 33 are very efficient in providing 4-alkyl-and 4-aryl 1-alkoxy-5-nitroisoquinolines. The Suzuki coupling with arylboronic acids is insensitive to electron-withdrawing (-CF 3 ) and electron-donating (-OMe) groups on the phenylboronic acid. Surprisingly, major steric bulk is also tolerated in the 35 coupling reaction, in that phenanthrene-9-boronic acid is also a satisfactory coupling partner in the formation of 35. Anal ogous couplings were not possible using the corresponding isoquinolin-1-ones 18 and 22, probably owing to poor solubil ity of these lactams. 1-Alkoxyisoquinolines can be considered 
Experimental
General 15 NMR spectra were recorded on JEOL Delta 270 and Varian Mercury 400 spectrometers of solutions in deuteriochloro form, unless otherwise stated; coupling constants (J) are given in Hz. Mass spectra were obtained using VG7070E and Bruker microTOF™ spectrometers in the ES + mode. IR spec 20 tra were measured on a Perkin-Elmer RXI FTIR spectrometer as KBr discs. The stationary phase for chromatography was silica gel. All reactions were carried out at ambient temperat ure, unless otherwise stated. Solvents were evaporated under reduced pressure. Melting points were determined using a 25 Reichert-Jung Thermo Galen instrument and are uncorrected. SPhos refers to 2-dicyclohexylphosphino-2',6'-dimethoxybi phenyl and Pd 2 dba 3 refers to tris(dibenzylideneacetone)dipall adium.
4-Bromo-5-nitroisoquinolin-1-one (18) and 4-bromo-3 30 hydroxy-5-nitro-3,4-dihydroisoquinolin-1-one (17)
Bromine (5.0 g, 32 mmol) in acetic acid (5.0 mL) was added slowly to a suspension of 16 (6.0 g, 32 mmol) in acetic acid (15 mL). The mixture was stirred at 60°C for 16 h, then cooled and poured onto ice-water (60 mL). The precipitate 35 was collected, washed (methanol) and dried. Chromatography (hexane / ethyl acetate 6:1) gave 18 (4.5 g, 52%) as a pale orange solid: mp 229-232°C; ν max 3467, 1674, 1534, 1368 cm 1 ; δ H ((CD 3 ) 2 CO) 7.73 (1 H, s, 3-H), 7.77 (1 H, t, J 7.8, 7-H), 8.10 (1 H, dd, J 7.8, 1.6, 6-H), 8.61 (1 H, dd, J 8.6, 1.9, 8- (1 H, dd, J 7.9, 1.5, 6-H), 8.30 (1 H, dd, J 7.7, 1.5, 8-H), 8.55 (1 H, br, NH).
4-Bromo-5-nitroisoquinolin-1-one (18) and 3-acetoxy-4 bromo-5-nitro-3,4-dihydroisoquinolin-1-one (19)
N-Bromosuccinimide (90 mg, 0.5 mmol) was stirred with 16 55 (100 mg, 0.5 mmol) in acetic acid (5 mL 
5-Amino-4-bromoisoquinolin-1(2H)-one (22)
Compound 18 (1 H, dd, J 8.2, 1.6, 6-H), 7.22 (1 H, s, 3-H), 7.25 (1 H, t, J 8.2, 7-H), 7.54 (1 H, dd, J 7.8, 1.2, 8-H), 11.34 (1 H, br s, NH); δ C ((CD 3 ) 2 SO) (HMQC / HMBC) 93. 10 (4 C), 115.83 (8-C), 119.17 (6-C), 119.42 (10-C) , 128.04 (3-C), 95 128.44 (9-C), 128.56 ( 
4-Bromo-1-chloro-5-nitroisoquinoline (23)
Oxalyl chloride (5.3 mL, 7 .67 g, 60.4 mmol) was added dropwise during 30 min to dry dimethylformamide (4.7 mL, 4.4 g, 100 60.4 mmol) in 1,2-dichloroethane (35 mL) at 0°C. The sus pension was stirred at room temperature for 10 min, then 18 (7.3 g, 27 mmol) was added. The mixture was then heated at 80°C for 6 h, allowed to cool and diluted with CH 2 Cl 2. Washing (water), drying and evaporation gave 23 (7.0 g, 89%) 105 as a yellow solid: mp 164-166°C; δ H 7.82 (1 H, t, J 7.6, 7-H), 8.01 (1 H, dd, J 7.6, 1.2, 6-H), 8.62 (1 H, s, 3-H), 8.65 (1 H, dd, J 7.6, 1.2, 8-H) ; δ C  112. 4, 127.1, 127.8, 128.2, 128.6, 131.0, 147.4, 147.6, 152 .0.
4-Bromo-1-methoxy-5-nitroisoquinoline (24)
Finely divided sodium (700 mg, 31 mmol) was added to 23 (5.0 g, 17 mmol) (3 H, s, Me), 7.63 (1 H, t, J 7.8, 7.88 (1 H, dd, J 7.8, 1.1, 8.29 (1 H, s, 8.48 (1 H, dd, J 7.8, 1.1, δ C 10 54.6, 104.2, 110.0, 121.9, 126.3, 126.9, 128.5, 146.2, 147.0, 160.3; Found: C, 42.43; H, 2.63; N, 9.69 4, 120.7, 124.5, 125.5, 50 127.4, 127.7, 127.8, 128.1, 128.4, 129.1, 137.5, 144.7, 147.6, 160.3; m/ 3, 114.2, 119.5, 121.2, 124.7, 125.8, 126.3, 127.8, 128.7, 129.3, 142.3, 146.8, 158.7; m/ (1 H, d, J 5.1, 3-H), 7.66 (1 H, t, J 7.8, 7-H), 8.13 (1 H, dd, J 7.8, 1.3, 6-H), 8.50 (1 H, dd, J 7.8, 1.3, 8-H), 11.64 (1 H, br, NH).
5-Amino-4-methylisoquinolin-1-one hydrochloride (29)
Compound 28 (116 mg, 0.56 mmol) was stirred with pallad 95 ium on charcoal (10%, 100 mg) in ethanol (14 mL) and aq. hydrochloric acid (34%, 0.4 mL) under hydrogen for 2 h. The suspension was filtered through Celite ® . The Celite ® pad and residue were suspended in water (100 mL) and heated. The hot suspension was filtered through a second Celite ® pad. 
